Sichenzia Ross Ference Carmel LLP Represents Impact Biomedical Inc. in Closing of $4.5 Million Initial Public Offering

Press Release – New York, NY – September 18, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Impact Biomedical Inc. (NYSE: IBO), a company discovering and developing new offerings in human healthcare and wellness, in the pricing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO”.

The Sichenzia Ross Ference Carmel LLP team was led by partner Darrin Ocasio and associate Jesse Blue.